SCWorx Corp.

SCWorx Corp. develops and markets health care information technology solutions and related services to improve healthcare processes and information flow within hospitals and other healthcare facilities in the United States. The company provides data content and services related to repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. It also offers virtualized item master file repair, expansion and automation; EMR management; CDM management; contract management; request for proposal automation; rebate management; integration of acquired management; big data analytics modeling; data integration and warehousing; and ScanWorx. In addition, the company operates an online event ticketing platform focused on serving regional mixed martial arts. In addition, it offers CageTix, a ticketing platform for mixed martial arts industry. Further, the company focuses on selling personal protective equipment and COVID-19 rapid test kits. It sells its solutions and services to hospitals and health systems through its direct sales force, and distribution and reseller partnerships. SCWorx Corp. is based in New York, New York.

SCWorx Corp. trades as WORX on NASDAQ. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.88M of revenue and -$4.44M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

SCWorx Corp. can be compared against peers such as Concord Medical Services Holdings Limited, CDT Equity Inc., Envoy Medical, Inc., Hepion Pharmaceuticals, Inc., NewGenIvf Group Limited, PetVivo Holdings, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $303,463, beta of 1.58, and return on equity of -62.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

WORX currently shows total debt of $1,539 and beta of 1.58. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: PRE 14A (2026-06-01 00:00:00), 10-Q (2026-05-15 00:00:00), SC 13G/A (2026-05-15 00:00:00), 8-K (2026-04-10 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.scworx.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.